Evaluate the efficacy of Zelnate for BRD treatment as measured by mortality.
In this study, healthy steers 3-4 months of age were randomly allocated into two groups (n=40 per group). Animals were challenged via intratracheal route (Mannheimia haemolytica) on Day 0. On Day 1 (24 hours later), the animals received intramuscular injection of either Zelnate or a placebo treatment.
On Day 1, overall morbidity was measured at 67.5%. Clinical examination and lung lesion scoring was performed on dead animals on Days 2-4, and lung lesion scoring on surviving animals was measured on Day 5. Cumulative incidence of death was measured at 11.3% on Day 5.
The chart shows cumulative mortality as observed from the day of challenge (Day 0) to Day 5 post-challenge.
*Statistically significant reduction (P < 0.05)
Zelnate, as a stand-alone therapy, has been shown to significantly reduce the risk of mortality when administered in the face of clinical BRD.
1Data on file. Bayer HealthCare Animal Health.